Biopharmaceutical company Pfizer Inc (NYSE:PFE) on Thursday announced positive topline results from the TALAPRO-2 study, which evaluated the efficacy of TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) in patients with metastatic castration-resistant prostate cancer (mCRPC).

The combination demonstrated a statistically significant improvement in overall survival (OS) compared to XTANDI alone, both in all-comers and in patients with homologous recombination repair (HRR) gene-mutated mCRPC.

These results mark a significant milestone for prostate cancer treatment, as TALZENNA plus XTANDI is the first PARP inhibitor plus ARPI combination to show such a benefit. Pfizer plans to submit the data to global health authorities for potential label updates.